Sort by
Refine Your Search
-
selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to
-
to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive
-
, synthetic chemistry and troubleshooting. Our main focuses are to improve the potency/efficacy and physicochemical as well as pharmacokinetics properties of the hit molecules through chemical modification
-
, empirical and structure-based target design, synthetic chemistry and troubleshooting. Our main focuses are to improve the potency/efficacy and physicochemical as well as pharmacokinetics properties of the hit
-
to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines
-
selves to work, and achieve their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring
-
technologies. Responsibilities The primary function of the fellow is to create and sustain the relevant connections with the diabetes scientific community to support FreeStyle Libre products. The fellow will
-
, acquired, life-threatening blood disorder, and an approved therapy for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), two rare and serious kidney
-
world, a therapy for paroxysmal nocturnal hemoglobinuria, a rare, acquired, life-threatening blood disorder, and an approved therapy for C3 glomerulopathy (C3G) or primary immune complex
-
disease, IgA nephropathy, primary membranous, nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global